Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience

Aim: To explore and compare the efficacy of standard (300 mg every 2 weeks) and extended (300 mg every 4 weeks) dosing regimens of lanadelumab for long-term prophylaxis of hereditary angioedema (HAE). Methods: We conducted a retrospective chart review of all patients with HAE on lanadelumab, which i...

Full description

Bibliographic Details
Main Authors: Mohamed Abuzakouk, PhD, Omar Ghorab, MB BCh BAO, Hamad Al-Hameli, MD, Fulvio Salvo, MD, Deepa Grandon, MBBS, Marcus Maurer, PhD
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:World Allergy Organization Journal
Subjects:
Lanadelumab
Hereditary angioedema
Prophylaxis
Real-life
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455122000400

Internet

http://www.sciencedirect.com/science/article/pii/S1939455122000400

Similar Items